MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer

Guohong Hu, Robert A. Chong, Qifeng Yang, Yong Wei, Mario A. Blanco, Feng Li, Michael Reiss, Jessie L.S. Au, Bruce Haffty, Yibin Kang

Research output: Contribution to journalArticle

292 Citations (Scopus)

Abstract

Targeted therapy for metastatic diseases relies on the identification of functionally important metastasis genes from a large number of random genetic alterations. Here we use a computational algorithm to map minimal recurrent genomic alterations associated with poor-prognosis breast cancer. 8q22 genomic gain was identified by this approach and validated in an extensive collection of breast tumor samples. Regional gain of 8q22 elevates expression of the metastasis gene metadherin (MTDH), which is overexpressed in more than 40% of breast cancers and is associated with poor clinical outcomes. Functional characterization of MTDH revealed its dual role in promoting metastatic seeding and enhancing chemoresistance. These findings establish MTDH as an important therapeutic target for simultaneously enhancing chemotherapy efficacy and reducing metastasis risk.

Original languageEnglish (US)
Pages (from-to)9-20
Number of pages12
JournalCancer Cell
Volume15
Issue number1
DOIs
StatePublished - Jan 6 2009

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Gene Expression
Drug Therapy
Therapeutics
Genes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Hu, Guohong ; Chong, Robert A. ; Yang, Qifeng ; Wei, Yong ; Blanco, Mario A. ; Li, Feng ; Reiss, Michael ; Au, Jessie L.S. ; Haffty, Bruce ; Kang, Yibin. / MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer. In: Cancer Cell. 2009 ; Vol. 15, No. 1. pp. 9-20.
@article{97848550bc7d41d98d7fb4ef3ce7b70d,
title = "MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer",
abstract = "Targeted therapy for metastatic diseases relies on the identification of functionally important metastasis genes from a large number of random genetic alterations. Here we use a computational algorithm to map minimal recurrent genomic alterations associated with poor-prognosis breast cancer. 8q22 genomic gain was identified by this approach and validated in an extensive collection of breast tumor samples. Regional gain of 8q22 elevates expression of the metastasis gene metadherin (MTDH), which is overexpressed in more than 40{\%} of breast cancers and is associated with poor clinical outcomes. Functional characterization of MTDH revealed its dual role in promoting metastatic seeding and enhancing chemoresistance. These findings establish MTDH as an important therapeutic target for simultaneously enhancing chemotherapy efficacy and reducing metastasis risk.",
author = "Guohong Hu and Chong, {Robert A.} and Qifeng Yang and Yong Wei and Blanco, {Mario A.} and Feng Li and Michael Reiss and Au, {Jessie L.S.} and Bruce Haffty and Yibin Kang",
year = "2009",
month = "1",
day = "6",
doi = "10.1016/j.ccr.2008.11.013",
language = "English (US)",
volume = "15",
pages = "9--20",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "1",

}

Hu, G, Chong, RA, Yang, Q, Wei, Y, Blanco, MA, Li, F, Reiss, M, Au, JLS, Haffty, B & Kang, Y 2009, 'MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer', Cancer Cell, vol. 15, no. 1, pp. 9-20. https://doi.org/10.1016/j.ccr.2008.11.013

MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer. / Hu, Guohong; Chong, Robert A.; Yang, Qifeng; Wei, Yong; Blanco, Mario A.; Li, Feng; Reiss, Michael; Au, Jessie L.S.; Haffty, Bruce; Kang, Yibin.

In: Cancer Cell, Vol. 15, No. 1, 06.01.2009, p. 9-20.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer

AU - Hu, Guohong

AU - Chong, Robert A.

AU - Yang, Qifeng

AU - Wei, Yong

AU - Blanco, Mario A.

AU - Li, Feng

AU - Reiss, Michael

AU - Au, Jessie L.S.

AU - Haffty, Bruce

AU - Kang, Yibin

PY - 2009/1/6

Y1 - 2009/1/6

N2 - Targeted therapy for metastatic diseases relies on the identification of functionally important metastasis genes from a large number of random genetic alterations. Here we use a computational algorithm to map minimal recurrent genomic alterations associated with poor-prognosis breast cancer. 8q22 genomic gain was identified by this approach and validated in an extensive collection of breast tumor samples. Regional gain of 8q22 elevates expression of the metastasis gene metadherin (MTDH), which is overexpressed in more than 40% of breast cancers and is associated with poor clinical outcomes. Functional characterization of MTDH revealed its dual role in promoting metastatic seeding and enhancing chemoresistance. These findings establish MTDH as an important therapeutic target for simultaneously enhancing chemotherapy efficacy and reducing metastasis risk.

AB - Targeted therapy for metastatic diseases relies on the identification of functionally important metastasis genes from a large number of random genetic alterations. Here we use a computational algorithm to map minimal recurrent genomic alterations associated with poor-prognosis breast cancer. 8q22 genomic gain was identified by this approach and validated in an extensive collection of breast tumor samples. Regional gain of 8q22 elevates expression of the metastasis gene metadherin (MTDH), which is overexpressed in more than 40% of breast cancers and is associated with poor clinical outcomes. Functional characterization of MTDH revealed its dual role in promoting metastatic seeding and enhancing chemoresistance. These findings establish MTDH as an important therapeutic target for simultaneously enhancing chemotherapy efficacy and reducing metastasis risk.

UR - http://www.scopus.com/inward/record.url?scp=57849134562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57849134562&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2008.11.013

DO - 10.1016/j.ccr.2008.11.013

M3 - Article

VL - 15

SP - 9

EP - 20

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 1

ER -